Analyst Rating Update on Endologix (ELGX)

Endologix (NASDAQ:ELGX) : Zacks Investment Research ranks Endologix (NASDAQ:ELGX) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 7 research analysts is 1.14, which indicates as a Strong Buy.

Endologix (NASDAQ:ELGX) : Currently there are 6 street experts covering Endologix (NASDAQ:ELGX) stock. The most bullish and bearish price target for the stock is $17 and $15 respectively for the short term. The average price target of all the analysts comes to $15.75. The estimated standard deviation from the target is $0.76.

For the current week, the company shares have a recommendation consensus of Buy. Also, Canaccord Genuity upgrades its view on Endologix (NASDAQ:ELGX) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. The rating by the firm was issued on June 13, 2016.

Endologix (NASDAQ:ELGX): stock turned positive on Tuesday. Though the stock opened at $11.73, the bulls momentum made the stock top out at $11.96 level for the day. The stock recorded a low of $11.63 and closed the trading day at $11.91, in the green by 2.41%. The total traded volume for the day was 1,096,922. The stock had closed at $11.63 in the previous days trading.

In an insider trading activity, Waller Gregory D, director of Endologix Inc /De/, unloaded 7,800 shares at an average price of $12.86 on June 3, 2016. The total amount of the transaction was worth $100,308, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.